8-K: Functional Brands posts FY25 profit, launches platform

Functional Brands reported FY2025 net income of $0.8M, stronger Q4 profitability, a major preferred stock financing, and new digital health and international initiatives.

Summary

• Reported FY2025 net income of $758,478 (diluted EPS $0.01) versus a net loss of $559,356 in 2024; Q4 2025 net income was $852,313 (diluted EPS $0.01) versus a net loss of $277,750 in Q4 2024.
• FY2025 revenue was $6,611,484, up 0.7% year over year; Q4 2025 revenue was $1,494,521, down ~11% year over year due to a shift in Amazon strategy from reseller to direct-to-consumer.
• FY2025 gross profit was $3,483,966 with gross margin of 52.7% (down 220 bps year over year) due primarily to inventory adjustments from exiting the hemp business; Q4 gross margin was 44.9% (down 1,400 bps).
• Operating performance remained negative: FY2025 operating loss was $1,398,572 and Q4 operating loss was $1,132,750.
• FY2025 other income benefited from a $419,947 ERTC refund and a $7,358,935 fair value decrease in derivative liabilities offset by a $5,294,242 loss on issuance of preferred stock derivative liability.
• Cash increased to $2,726,696 at December 31, 2025 from $211,642 a year earlier, aided by $8,000,000 proceeds from preferred stock issuance.
• Balance sheet improved to positive stockholders’ equity of $1,541,331 at year-end 2025 from a deficit of $(118,577) at year-end 2024; current derivative liabilities stood at $3,306,745.
• Shares outstanding increased to 18,704,649 at December 31, 2025 from 6,694,880 at December 31, 2024.
• Launched Tru2u.health in February 2026, expanded Kirkman with new product bundles (December and January), and formed a strategic partnership with iHerb to expand P2i by Kirkman internationally.
• Management highlighted transformation initiatives aimed at sustainable, profitable growth and a scalable, digitally native growth engine.

Sentiment

Score: 6

Explanation: StockSavvy.ai views the return to profitability, stronger cash position, and strategic launches positively, but notes operating losses, dilution, and derivative overhang temper the outlook.

Positives

• Return to profitability: FY2025 net income of $758,478 and Q4 2025 net income of $852,313 versus prior-year losses.
• Stable full-year revenue: FY2025 revenue of $6,611,484, up 0.7% year over year, reflecting stability of the Kirkman business.
• Stronger liquidity: Year-end cash of $2,726,696 (up from $211,642) following $8,000,000 preferred stock financing.
• Equity inflection: Stockholders’ equity improved to $1,541,331 from a $(118,577) deficit.
• Strategic execution: Launch of Tru2u.health (digital health platform), two new Kirkman product bundles, and iHerb partnership expanding P2i by Kirkman internationally.
• Reduced leverage in certain areas: Payable for acquisition reduced to $0 from $2,342,366; line of credit reduced to $8,109 from $32,235.
• Non-cash derivative fair value decrease of $7,358,935 supported reported earnings.

Negatives

• Top-line softness in Q4: Revenue declined ~11% year over year to $1,494,521 due to Amazon channel shift.
• Margin pressure: Q4 gross margin fell 1,400 bps to 44.9%; FY gross margin declined 220 bps to 52.7% due to inventory adjustments tied to exiting the hemp business.
• Core operations loss-making: FY2025 operating loss of $1,398,572 and Q4 operating loss of $1,132,750.
• Negative operating cash flow: $(1,271,544) in FY2025.
• Higher operating costs: FY2025 G&A expenses rose to $4,250,124 from $3,259,623; sales and marketing to $632,414 from $576,315.
• Derivative overhang: Current derivative liabilities of $3,306,745 at year-end 2025 and a $5,294,242 loss on issuance of preferred stock derivative liability.
• Shareholder dilution: Common shares outstanding increased to 18,704,649 from 6,694,880; preferred stock activity included dividend accrual of $78,873.

Risks

• Forward-looking statements are subject to significant known and unknown risks, uncertainties, and factors beyond control that could cause actual results to differ materially.
• Uncertainty regarding the closing and anticipated benefits of a private placement referenced in the forward-looking statements.

Future Outlook

Management is positioning for scalable, profitable growth through the Tru2u.health digital platform (integrating peptide solutions and GLP-1-based weight programs), expansion of the Kirkman portfolio, and international distribution of P2i by Kirkman via iHerb; no quantitative guidance was provided.

Management Comments

• Delivered another year of strong bottom-line results while transforming the business model.
• Launched Tru2u.health to create a scalable, digitally native growth engine integrating GLP-1-based weight management, telehealth, peptide solutions, and clean supplements.
• Expanded the Kirkman brand with Skin, Beauty & Anti-Aging and Detox Aid bundles.
• Established a strategic partnership with iHerb to distribute P2i by Kirkman to international markets, expanding the addressable market.
• Initiatives lay a strong foundation for sustainable, profitable growth and differentiate the company in the marketplace.

Industry Context

StockSavvy.ai notes that the pivot toward a digital health platform with GLP-1 programs aligns with broader trends seen at telehealth and consumer wellness peers (e.g., Hims & Hers and WeightWatchers’ GLP-1 offerings), while international marketplace distribution via iHerb is a common route for supplements brands to scale globally; however, gross margin compression and reliance on non-operating gains lag the profitability profile of scaled supplement peers.

Comparison to Industry Standards

• Gross margin: FY2025 at 52.7% trails many mature supplements peers (often mid-50s to mid-60s) such as Thorne or larger CPG supplement portfolios, reflecting inventory adjustments and channel mix.
• Operating margin: Negative operating income contrasts with profitable peers in the supplement sector; the business remains sub-scale relative to mid-cap peers.
• Growth channels: Adoption of GLP-1 telehealth programs mirrors moves by Hims & Hers and WeightWatchers to capture weight management demand; execution and unit economics will be key versus those scaled platforms.
• International expansion: Partnering with iHerb is consistent with industry practice for cross-border reach; success typically depends on brand awareness, regulatory compliance, and supply chain reliability.
• Capital structure: Use of preferred stock with derivative features is more common among micro-cap issuers than established peers, often introducing EPS volatility and potential overhang.

Related Party Transactions

• Loans payable (related party): $61,642 current and $244,509 non-current at December 31, 2025.
• Supplemental disclosure notes a $225,000 related party loan in 2025.

Stakeholder Impact

• Shareholders: Dilution from 6,694,880 to 18,704,649 common shares outstanding; equity turned positive to $1,541,331; derivative liabilities ($3,306,745 current) may add share price volatility; preferred dividend of $78,873 accrued.
• Customers: New digital health platform (Tru2u.health) and product bundles enhance offering breadth; iHerb partnership increases international access to P2i by Kirkman.
• Creditors: Liquidity improved with $2,726,696 cash and reduced payable for acquisition to $0, supporting obligations.
• Employees/Partners: Strategic focus on innovation and digital channels may support growth initiatives and operational priorities.

Next Steps

• Scale the Tru2u.health platform integrating GLP-1 programs, peptides, telehealth, and supplements.
• Expand international distribution of P2i by Kirkman through the iHerb partnership.
• Continue transitioning and optimizing the Amazon direct-to-consumer model.
• Advance product innovation under the Kirkman brand following recent bundle launches.

Key Dates

Recommendation

Profitability and liquidity improved, and strategic initiatives expand growth prospects; however, core operations remain loss-making, Q4 revenue declined, margins compressed, dilution was significant, and derivative liabilities present ongoing overhang. A neutral stance is warranted pending evidence of sustained organic growth and operating margin improvement.

Keywords

Functional Brands, MEHA, Kirkman, P2i by Kirkman, Tru2u.health, GLP-1, digital health, iHerb partnership, prenatal vitamins, wellness supplements, Amazon direct-to-consumer, hemp business exit, preferred stock, derivative liabilities, ERTC refund, earnings, gross margin